SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001628280-23-012594
Filing Date
2023-04-24
Accepted
2023-04-24 17:15:31
Documents
20

Document Format Files

Seq Description Document Type Size
1 DEF 14A vnda-20230424.htm   iXBRL DEF 14A 1364526
6 vnda-20230424_g1.jpg GRAPHIC 24955
7 vnda-20230424_g2.jpg GRAPHIC 196043
8 vnda-20230424_g3.jpg GRAPHIC 330173
9 vnda-20230424_g4.jpg GRAPHIC 108278
10 vnda-20230424_g5.jpg GRAPHIC 491565
11 vnda-20230424_g6.jpg GRAPHIC 270098
  Complete submission text file 0001628280-23-012594.txt   5400310

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vnda-20230424.xsd EX-101.SCH 3589
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT vnda-20230424_def.xml EX-101.DEF 4740
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vnda-20230424_lab.xml EX-101.LAB 6593
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vnda-20230424_pre.xml EX-101.PRE 3726
14 EXTRACTED XBRL INSTANCE DOCUMENT vnda-20230424_htm.xml XML 171619
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-34186 | Film No.: 23840936
SIC: 2834 Pharmaceutical Preparations